spendergast Informed Prostate Cancer Patient: It's a Bust: Adding Immunotherapy No Benefit in mCRPC

Wednesday, April 29, 2020

It's a Bust: Adding Immunotherapy No Benefit in mCRPC

It's a Bust: Adding Immunotherapy No Benefit in mCRPC: The immune checkpoint inhibitor atezolizumab was added to standard treatment with enzalutamide in men with metatastic castration-resistant prostate cancer.

No comments:

Subscribe to: Post Comments (Atom)